Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

August 10, 2026

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

BSE CODE: 543329

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE SYMBOL: WINDLAS

Dear Sir/ Madam,

Ref: Compliance of Regulation 33 and Regulation 30 of the SEBI (LODR) Regulations, 2015

Sub: Outcome of the Board Meeting held on August 10, 2026

We wish to inform you that the Board of Directors at its Meeting held on Monday, August 10, 2026, approved the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.

In this regard we enclose the following:

i. Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
ii. Limited Review Report of the Auditors on the Standalone Financial Results for the Quarter ended June 30, 2026.

The meeting of the Board of Directors commenced at 2.30 P.M. and concluded at 3.15 P.M.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

ANANTA NARAYAN PANDA
2026.08.10 15:17:37 +05'30'
11.0.10

Ananta Narayan Panda
Company Secretary & Compliance Officer

Encl: as above

J. C. BHALLA & CO.
CHARTERED ACCOUNTANTS

BRANCH OFFICE : B-5, SECTOR-6, NOIDA - 201 301 (U.P.)
TEL. : +91 - 120 - 4241000, FAX : +91-120-4241007
E-MAIL : taxaid@jcbhalla.com

Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Windlas Biotech Limited

1. We have reviewed the accompanying statement of unaudited financial results of Windlas Biotech Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended'

2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind-AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

J.C. BHALLA & CO. Chartered Accountants

5. Other Matter

We draw attention to Note 9 to the accompanying Statement, which states that pursuant to the filing for dissolution of Windlas Inc., USA, a wholly owned non-operating subsidiary of the Company, with the Delaware Division of Corporations and pursuant to the Board Resolution dated February 5, 2026, the said subsidiary stands dissolved with effect from March 31, 2026. Accordingly, with effect from April 1, 2026, the Company is no longer required to prepare consolidated financial statements.

Our conclusion is not modified in respect of this matter.

For **J C Bhalla & Co.**
Chartered Accountants
Firm Regn. No. 001111N

Anshuman Mallick
Partner
Membership No. 547705
UDIN: 26547705DIVMXD8430

Place: Noida
Date : August 10, 2026

Windlas Biotech Limited
CIN: L74899UR2001PLC033407
Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India
Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com
Statement of unaudited financial results for the quarter ended 30th June'2026
(All amounts in Indian Rupees in millions, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	30th June, 2026 (Unaudited)	31st March, 2026 (Audited) (refer note no 10)	30th June, 2025 (Unaudited)	31st March, 2026 (Audited)
Revenue from Operations	2,480.99	2,384.99	2,100.90	9,040.89
Other Income	51.13	43.98	52.39	178.04
Total Income	**2,532.12**	**2,428.97**	**2,153.29**	**9,218.93**
Expenses				
Cost of Material Consumed	1,687.41	1,454.63	1,254.54	5,501.30
Changes in Inventories of Finished goods and Work-in-progress	(160.12)	15.88	42.76	71.04
Employee Benefit Expenses	444.34	413.69	322.31	1,520.93
Finance Cost	16.50	14.75	10.57	48.25
Depreciation and Amortization expense	72.06	79.99	74.48	307.43
Other Expenses	242.57	248.41	216.05	900.67
Total Expenses	**2,302.76**	**2,227.35**	**1,920.71**	**8,349.62**
Profit before tax	**229.36**	**201.62**	**232.58**	**869.31**
Income tax expense				
Current tax	63.54	48.10	55.53	206.99
Deferred Tax	(10.71)	(6.64)	0.40	(2.03)
Total Tax Expense	52.83	41.46	55.93	204.96
Profit for the year	**176.53**	**160.16**	**176.65**	**664.35**
Other Comprehensive Income				
A (i) Items that will not be reclassified to profit or loss:				
Remeasurement of defined benefit plans- gain/(loss)	(0.61)	1.04	0.48	1.49
Income tax effect	0.15	(0.27)	(0.12)	(0.38)
Other Comprehensive Income for the year	**(0.46)**	**0.77**	**0.36**	**1.11**
Total Comprehensive Income for the year	**176.07**	**160.93**	**177.01**	**665.46**
Paid up equity share capital (Face value of Rs. 5/- per share)	103.18	105.53	104.80	105.53
Total Reserves	**-**	**-**	**-**	**5,702.80**
Earnings per share*:				
Basic (in Rs.)	8.46	7.60	8.43	31.59
Diluted (in Rs.)	8.32	7.50	8.34	31.14
Face value per share (in Rs)	5.00	5.00	5.00	5.00

*EPS are not annualised

Notes :

1. The unaudited financial results of the company for the quarter ended as on 30th June, 2026 has been prepared as per regulation 33 of the SEBI LODR (Listing Obligation and Disclosure Requirements) regulation 2015.

2.The financial results have been reviewed by the audit committee and approved by the board of directors at their meeting held on 10th August , 2026 and limited review has been carried out by statutory auditors.

3.The financial results have been prepared in accordance with the Indian Accounting Standards notified under section 133 of the companies act, 2013, read with the companies (Indian accounting standards) Rules, 2015, as amended.

4. According to Indian Accounting Standard (Ind-AS) 108 on “Operating Segment” the Company has only one primarily reportable segment i.e. "Pharmaceuticals"

Windlas Biotech Limited
CIN: L74899UR2001PLC033407
Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India
Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com
Statement of unaudited financial results for the quarter ended 30th June'2026
(All amounts in Indian Rupees in millions, unless otherwise stated)

5. During the period, the Company granted 21,250 units under the WBL Plan 2025 and 14,125 options under the ESOS Scheme 2023 on 21st May, 2026, at exercise prices of Rs. 5 per unit and Rs. 600 per option, respectively. In the previous year, on 15th September, 2025, the Company granted 570,500 units under the WBL Plan 2025 at an exercise price of Rs. 5 per unit.
During the previous year, the Company allotted 146,918 equity shares of face value Rs. 5 each to eligible employees pursuant to its employee stock option schemes, resulting in an increase in the issued share capital from Rs. 104.80 million to Rs. 105.53 million.
The Company recognized employee share-based payment expense of Rs. 71.62 million for the quarter ended 30th June, 2026 (year ended 31st March, 2026: Rs. 166.11 million).

6. Pursuant to the Board Resolution dated 17th April, 2026, the Company completed the buyback of 470,000 fully paid-up equity shares through the Tender Offer route at a price of Rs. 1,000 per share, aggregating to Rs. 470,000,000. Consequently, the issued, subscribed and paid-up equity share capital of the Company stands reduced to 20,636,229 equity shares of face value Rs. 5 each. The Company has created Capital Redemption Reserve amounting to INR 2.35 millions, equivalent to the nominal value of the shares bought back from securities premium.

7. The Government of India has consolidated various labour legislations into four labour codes, namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes became effective from 21st November, 2025. Based on the assessment performed by the company and the information presently available, including the draft rules, clarifications and guidance issued by the relevant authorities and the Institute of Chartered Accountants of India, the company has concluded that the impact of the Codes on its financial statements for the year ended 31st March, 2026 is not material. The company will continue to monitor developments relating to the implementation of the Codes and the notification of Central and State Rules and will recognise the impact, if any, in the period in which the same can be reasonably estimated.

8. The Board of Directors at its meeting held on 21st May, 2026, had proposed dividend of Rs. 6.30 Per share for the year ended 31st March, 2026. The shareholders in the annual general meeting held on 23rd July, 2026 have approved the same. The aggregate dividend payout to shareholders amounted to Rs. 130.01 million paid on 31st July, 2026.

9. Pursuant to the filing for dissolution of Windlas Inc., USA (a wholly owned non-operating subsidiary) with the Delaware Division of Corporations vide Board Resolution dated 5th February, 2026 of the Company, the said subsidiary stands dissolved with effect from 31st March, 2026. Hence, the Company's consolidated financial statements are not being prepared w.e.f. 01st April, 2026.

10. The figures for the quarter ended 31st March 2026 are the balancing figure between the audited figures in respect of the year ended 31st March, 2026 and the published unaudited figures for the nine months ended 31st December, 2025, which were subject to a limited review by the statutory auditor.

For and on behalf of the board of directors of Windlas Biotech Limited

Hitesh Windlass
Managing Director
DIN: 02030941

Place: Gurugram
Date: 10th August, 2026